Publications by authors named "Royce A Morrison"

Claim this Profile
C
Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours.
Cathrine Leonowens, Carolyn Pendry, John Bauman, Graeme C Young, May Ho, Royce A Morrison

Br J Clin Pharmacol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers.
May Y K Ho, Michael J Morris, Jill L Pirhalla, John W Bauman, Carolyn B Pendry, Royce A Morrison

Xenobiotica· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism and disposition of oral dabrafenib in cancer patients: proposed participation of aryl nitrogen in carbon-carbon bond cleavage via decarboxylation following enzymatic oxidation.
David A Bershas, Daniele Ouellet, Donna B Mamaril-Fishman, Noelia Nebot, Stanley W Carson, Royce A Morrison

Drug Metab Dispos· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concomitant oral and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with BRAF V600 mutation-positive solid tumors.
Cathrine L Denton, Elisabeth Minthorn, Stanley W Carson, Graeme C Young, Lauren E Richards-Peterson, Royce A Morrison

J Clin Pharmacol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist.
Brendan M Johnson, Laurel M Adams, Ke Zhang, Shelby D Gainer, Lyndon C Kirby, Royce A Morrison

J Clin Pharmacol· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis